Research

Hormonal

AAS users engage in extensive polypharmacy (averaging 11.1 agents/year) to mitigate adverse effects such as gynecomastia, testicular atrophy, and sexual dysfunction, using agents like tamoxifen, clomiphene, and PDE5 inhibitors.

If you are using AAS, you are likely also using other drugs to manage side effects like gynecomastia or low testosterone. This polypharmacy increases health risks. Be aware of what you are taking and why. Regular blood work is essential to monitor the impact of these combined substances.

ModerateSupportsMEDIUM confidence
The AAS users incorporated over 2.5 times more PEAs into their routine than the nonusers (11.1 vs 4.3 agents, p<0.001)... Tamoxifen and anastrazole... are commonly taken by AAS users to treat or prevent AAS-induced gynecomastia. Clomiphene and human chorionic gonadotropin... are used to treat or prevent AAS-induced testicular atrophy and withdrawal.
Eric J. Ip et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2011

Why this rating

Self-reported data on PEA use; cross-sectional design.

Source

The Anabolic 500 Survey: Characteristics of Male Users versus Nonusers of Anabolic‐Androgenic Steroids for Strength Training

Eric J. Ip et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2011

DOI 10.1592/phco.31.8.757

cross_sectional · n=1277Cited 188×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →